A recent study indicates that treatment of insomnia with cognitive behavioral therapy for insomnia (CBT-I) has an overall benefit in the prevention of incident and recurrent major depression in older adults with insomnia disorder compared with sleep education therapy (SET).
In children and adolescents with autism spectrum disorder (ASD), intranasal oxytocin did not improve social interaction or other measures of social function related to ASD, the phase II SOARS-B* trial suggests.
A recent study led by researchers from The University of Hong Kong (HKU) highlights the transient and heterogenous nature of psychotic experiences (PEs), showing that multiple PEs and the hallucination subtype of PEs may be specific indices of poor mental health condition.
Sleeping between 10–11 pm is associated with a decreased risk of developing cardiovascular disease (CVD) compared with earlier or later bedtimes, according to a study — suggesting that this timing represents the optimal sleeping time for better heart health.
Lysergic acid diethylamide (LSD) may be beneficial for use in psychological-assisted therapy, with a recent study reporting that a 100-mcg dose of LSD enhances the ability of the mind to function efficiently and effectively across a range of situations, according to a study.
New drug applications approved by US FDA as of 01-15 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
For many healthcare workers involved in palliative care, the intense emotions associated with end-of-life caregiving make them susceptible to a mental and physical fallout—a condition defined as burnout.